Company Filing History:
Years Active: 2019
Title: Thomas Matthew Webb: Innovator in Antigen Binding Proteins
Introduction
Thomas Matthew Webb is a notable inventor based in Brentford, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding proteins. With a total of 2 patents to his name, Webb's work focuses on advancing medical science and improving therapeutic options.
Latest Patents
Webb's latest patents include innovative applications related to antigen binding proteins. The first patent discloses antigen binding proteins that specifically bind to Lymphocyte Activation Gene 3 (LAG-3). This application is particularly significant as it addresses the depletion of LAG-3+ activated T cells, which can have important implications in cancer therapy. The second patent also pertains to anti-LAG-3 binding proteins, further emphasizing his commitment to exploring the potential of LAG-3 in therapeutic contexts.
Career Highlights
Thomas Matthew Webb is currently associated with GlaxoSmithKline Intellectual Property Development Limited. His role in this esteemed organization allows him to leverage his expertise in biotechnology and patent development. Webb's contributions are vital in pushing the boundaries of what is possible in medical research and treatment.
Collaborations
Throughout his career, Webb has collaborated with notable colleagues, including Paul Andrew Hamblin and Alan Peter Lewis. These partnerships have likely enriched his work and expanded the impact of his inventions.
Conclusion
In summary, Thomas Matthew Webb is a distinguished inventor whose work in antigen binding proteins is paving the way for advancements in medical therapies. His patents reflect a deep understanding of biotechnology and a commitment to improving health outcomes.